Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
Biomark Insights ; 11: 77-84, 2016.
Article in English | MEDLINE | ID: mdl-27257368

ABSTRACT

The aim of this study was to set up an ex vivo model for renal interstitial fibrosis in order to investigate the extracellular matrix (ECM) turnover profile in the fibrotic kidney. We induced kidney fibrosis in fourteen 12-week-old male Sprague Dawley rats by unilateral ureteral obstruction (UUO) surgery of the right ureter. The left kidney (contralateral) was used as internal control. Six rats were sham operated and used as the control group. Rats were terminated two weeks after the surgery; the kidneys were excised and precision-cut kidney slices (PCKSs) were cultured for five days in serum-free medium. Markers of collagen type I formation (P1NP), collagen type I and III degradation (C1M and C3M), and α-smooth muscle actin (αSMA) were measured in the PCKS supernatants by enzyme-linked immunosorbent assay. P1NP, C1M, C3M, and α-SMA were increased up to 2- to 13-fold in supernatants of tissue slices from the UUO-ligated kidneys compared with the contralateral kidneys (P < 0.001) and with the kidneys of sham-operated animals (P < 0.0001). The markers could also reflect the level of fibrosis in different animals. The UUO PCKS ex vivo model provides a valuable translational tool for investigating the extracellular matrix remodeling associated with renal interstitial fibrosis.

2.
J Clin Oncol ; 30(17): 2070-8, 2012 Jun 10.
Article in English | MEDLINE | ID: mdl-22564989

ABSTRACT

PURPOSE: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. PATIENTS AND METHODS: Patients previously treated with one to two chemotherapy regimens (including one platinum-based regimen) for recurrent NSCLC, and for whom erlotinib was indicated, were randomly assigned (1:1) to sunitinib 37.5 mg/d plus erlotinib 150 mg/d or to placebo plus erlotinib 150 mg/d, stratified by prior bevacizumab use, smoking history, and epidermal growth factor receptor expression. The primary end point was OS. Key secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. RESULTS: In all, 960 patients were randomly assigned, and baseline characteristics were balanced. Median OS was 9.0 months for sunitinib plus erlotinib versus 8.5 months for erlotinib alone (hazard ratio [HR], 0.922; 95% CI, 0.797 to 1.067; one-sided stratified log-rank P = .1388). Median PFS was 3.6 months versus 2.0 months (HR, 0.807; 95% CI, 0.695 to 0.937; one-sided stratified log-rank P = .0023), and ORR was 10.6% versus 6.9% (two-sided stratified log-rank P = .0471), respectively. Treatment-related toxicities of grade 3 or higher, including rash/dermatitis, diarrhea, and asthenia/fatigue were more frequent in the sunitinib plus erlotinib arm. CONCLUSION: In patients with refractory NSCLC, sunitinib plus erlotinib did not improve OS compared with erlotinib alone, but the combination was associated with a statistically significantly longer PFS and greater ORR. The incidence of grade 3 or higher toxicities was greater with combination therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Indoles/administration & dosage , Lung Neoplasms/drug therapy , Pyrroles/administration & dosage , Quinazolines/administration & dosage , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Double-Blind Method , Erlotinib Hydrochloride , Female , Humans , Male , Middle Aged , Placebos , Proportional Hazards Models , Smoking , Sunitinib , Treatment Outcome
3.
Eur Spine J ; 20(11): 1892-8, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21766167

ABSTRACT

INTRODUCTION: There is increasing awareness of the need for pedicle screw constructs in the treatment of spinal deformities in very young children. However, the long-term effects of pedicle screws on the immature spine are still unclear. We used a porcine model to analyze the morphological changes of the spinal canal and vertebral body in response to the placement of pedicle screws. METHODS: 13 newborn pigs were operated on. Each pig received a single pedicle screw at the L2 level. After a tenfold increase in body weight (7 months later), the symmetry of the spinal canal and vertebral body was measured on CT scans of the investigational (L2) and control (L3) levels in terms of the angulations of the instrumented and non-instrumented halves of the vertebral body and spinal canal. RESULTS: After 7 months, the normalised vertebral body angle had reduced on the non-screw side and increased on the screw side, indicating asymmetry in vertebral body growth in the axial plane. The difference was significant (p = 0.009). However, there was no significant difference between the screw and non-screw sides for the spinal canal angles at the L2 level at either the intraoperative or 7-month follow-up assessment (each p > 0.05). CONCLUSIONS: Pedicle screws in the immature porcine spine have a significant effect on the development of the vertebral body. However, in the present study, no corresponding alteration of the morphology of the spinal canal was observed. Our results provide further support for the existing arguments in favour of pedicle screws when weighing up the many factors to be considered in creating a treatment plan for early onset scoliosis.


Subject(s)
Bone Screws/adverse effects , Lumbar Vertebrae/growth & development , Lumbar Vertebrae/surgery , Spinal Fusion/adverse effects , Animals , Female , Male , Models, Animal , Prospective Studies , Scoliosis/surgery , Swine
4.
Am J Physiol Regul Integr Comp Physiol ; 284(2): R540-9, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12388448

ABSTRACT

Inhibitor of differentiation-2 (Id2) is a basic helix-loop-helix protein that acts as a negative regulator of the myogenic regulatory transcription factor family, but Id2 has also been implicated in apoptosis in several cell lines. In this study, we tested the hypothesis that Id2 has a role in both apoptosis-associated muscle atrophy and muscle hypertrophy. A weight corresponding to 12% of the body weight was attached to one wing of Japanese quail to induce hypertrophy in the patagialis (PAT) muscle. Birds in group 1 were killed after 5 (n = 8), 7 (n = 10), or 14 days (n = 10) of loading. The left wing was loaded for 14 days in group 2 birds, and then the weight was removed and the PAT was examined after 7 (n = 10), 14 (n = 10), or 21 (n = 5) days of unloading. A time-released bromodeoxyuridine (BrdU) pellet was implanted subcutaneously with wing weighting to identify activated satellite cells during loading. The left wing was loaded for 14 days, unloaded for 14 days, and then the weight was reattached for a subsequent 7 (n = 10) or 14 days (n = 10) in group 3 birds. BrdU was implanted on the second loading phase in this group. Id2 mRNA as measured by kinetic PCR increased by 3.9-, 2.7-, and 1.6-fold, relative to control levels after 7, 14, and 21 days of unloading (group 2). Id2 protein as estimated by Western blots increased by 1.5-, 1.4-, and 0.75-fold after 7, 14, and 21 days of unloading (group 2). Muscle unloading induced apoptosis, because poly(ADP-ribose) polymerase-(PARP)-positive nuclei increased and caspase 8 levels increased by 2.6- and 1.7-fold after 7 or 14 days of unloading, respectively (group 2). Although BrdU-positive nuclei increased during loading (groups 1 and 3), 50% failed to survive during unloading (group 2). Id2 mRNA increased by 2.2- and 1.8-fold after 5 and 7 days of loading, respectively, but decreased to control levels by 14 days of loading in group 1. Id2 protein levels increased 2.1-fold after 5 days of loading (group 1). In contrast, Id2 did not increase in reloaded muscles of group 3 birds. These data suggest that Id2 may have a role in apoptosis-associated atrophy of skeletal muscles, but its role in muscle hypertrophy is less clear.


Subject(s)
Apoptosis , Coturnix/physiology , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Muscle, Skeletal/metabolism , Repressor Proteins , Satellite Cells, Skeletal Muscle/metabolism , Transcription Factors/metabolism , Weight-Bearing/physiology , Animals , Blotting, Western , Bromodeoxyuridine , Caspases/metabolism , Cell Division , DNA-Binding Proteins/genetics , Female , Immunohistochemistry , Inhibitor of Differentiation Protein 2 , Male , Muscle Proteins/genetics , Muscle, Skeletal/cytology , Organ Size , Polymerase Chain Reaction , RNA, Messenger/genetics , RNA, Messenger/metabolism , Satellite Cells, Skeletal Muscle/physiology , Time Factors , Transcription Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...